בינוקריט 5000 יחבל 0.5 מל Israeli - Kiebrania - Ministry of Health

בינוקריט 5000 יחבל 0.5 מל

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 5000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

בינוקריט 6000 יחבל  0.6 מל Israeli - Kiebrania - Ministry of Health

בינוקריט 6000 יחבל 0.6 מל

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 6000 iu / 0.6 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

בינוקריט 10000 יחבל  1 מל Israeli - Kiebrania - Ministry of Health

בינוקריט 10000 יחבל 1 מל

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 10000 iu / 1 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

בינוקריט 20000 יחבל  0.5 מל Israeli - Kiebrania - Ministry of Health

בינוקריט 20000 יחבל 0.5 מל

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 20000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

בינוקריט 3000 יחבל  0.3 מל Israeli - Kiebrania - Ministry of Health

בינוקריט 3000 יחבל 0.3 מל

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 3000 iu / 0.3 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

בינוקריט 40000 יחבל  1 מל Israeli - Kiebrania - Ministry of Health

בינוקריט 40000 יחבל 1 מל

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 40000 iu / 1 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

אדווקט לחתולים וחמוסים וטרינרי Israeli - Kiebrania - Ministry of Health

אדווקט לחתולים וחמוסים וטרינרי

lidorr elements ltd - imidacloprid; moxidectin - תמיסה - imidacloprid 100 mg/ml; moxidectin 10 mg/ml - cats:for cats suffering from or at risk from mixed parasitic infections : for the treatment and prevention of flea infestation (ctenocephalides felis) treatment of ear mit infestation (otodectes cynotis) prevention of heartworm disease (l3 and l4 larvae of dirofilaria immitis) and treatment of infections with gastrointestinal nematodes (l4 larve immature adults and adults of toxocara cati ancylostoma tubaeforne). the product can be used as part of a treatment strategy for flea allergy dermatitis (fad).ferrets:for ferrets suffering from, or at risk from, mixed parasitic infections : for the treatment and prevention of flea infestation (ctenocephalidas felis ) and the prevention of heartworm disease (l3 and l4 larvae of dirofilaria immitis)

סטמריל Israeli - Kiebrania - Ministry of Health

סטמריל

sanofi israel ltd - yellow fever virus strain 17d204 (substrain ab237) - אבקה וממס להכנת תרחיף להזרקה - yellow fever virus strain 17d204 (substrain ab237) - yellow fever, live attenuated

פרדקסה 150 Israeli - Kiebrania - Ministry of Health

פרדקסה 150

boehringer ingelheim israel ltd. - dabigatran etexilate as mesilate - קפסולות - dabigatran etexilate as mesilate 150 mg - dabigatran etexilate - dabigatran etexilate - prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation.

זוטקטרה Israeli - Kiebrania - Ministry of Health

זוטקטרה

kamada ltd, israel - human hepatitis b immunoglobulin - תמיסה להזרקה - human hepatitis b immunoglobulin 500 iu - hepatitis b immunoglobulin - hepatitis b immunoglobulin - prevention of hepatitis b virus (hbv) re-infection in hbv-dna negative patients ?6 months after liver transplantation for hepatitis b induced liver failure.zutectra is indicated in adults only.the concomitant use of adequate virostatic agents should be considered, if appropriate, as standard of hepatitis b re-infection prophylaxis.